OBJECTIVE: Interleukin 33 (IL33) is a cytokine belonging to the IL1 family and it binds to a complex of the ST2L/IL1 receptor accessory protein (IL1RAcP). To define the role of IL33 in fibrogenesis of the pancreas, the expression of IL33, ST2L and IL1RAcP was examined in chronic pancreatitis tissues. The effects of IL33 on the functions of human pancreatic myofibroblasts were also investigated. METHODS: Tissue samples were obtained surgically. The expression of IL33, ST2L and IL1RAcP was evaluated by standard immunohistochemical procedures. Messenger RNA expression for IL33, ST2L and IL1RAcP was analysed by northern blotting and real-time PCR analyses, and protein expression was assessed by western blotting and ELISA. Cell proliferation and migration were assessed by a (3)H-thymidine incorporation assay and the modified Boyden chamber assay, respectively. RESULTS: IL33, ST2L and IL1RAcP were expressed by alpha-SMA-positive myofibroblasts in the fibrosis of chronic pancreatitis. In human pancreatic myofibroblasts, IL33 was weakly immunoexpressed without any stimuli, and this was markedly enhanced by IL1beta, tumour necrosis factor alpha (TNFalpha) and lipopolysaccharide (LPS) via the mitogen-activated protein kinase (MAPK)-dependent AP-1 activation pathway. ST2L mRNA was weakly detected in unstimulated cells, and IL4 and interferon gamma (IFNgamma) strongly enhanced ST2L expression via STAT6 and STAT1 signalling, respectively. IL33 rapidly induced the phosphorylation of MAPKs and IkappaBalpha, and enhanced the expression of inflammatory mediators (IL6, IL8, IP-10, Gro-alpha, Gro-beta and MCP-1) in IL4- or IFNgamma-pretreated cells. IL33 stimulated the proliferation and migration of pancreatic myofibroblasts. CONCLUSIONS: IL33 and its receptor complex (ST2L and IL1RAcP) constitute a novel signalling system which may play an important role in the pathogenesis of chronic pancreatitis.
OBJECTIVE:Interleukin 33 (IL33) is a cytokine belonging to the IL1 family and it binds to a complex of the ST2L/IL1 receptor accessory protein (IL1RAcP). To define the role of IL33 in fibrogenesis of the pancreas, the expression of IL33, ST2L and IL1RAcP was examined in chronic pancreatitis tissues. The effects of IL33 on the functions of humanpancreatic myofibroblasts were also investigated. METHODS: Tissue samples were obtained surgically. The expression of IL33, ST2L and IL1RAcP was evaluated by standard immunohistochemical procedures. Messenger RNA expression for IL33, ST2L and IL1RAcP was analysed by northern blotting and real-time PCR analyses, and protein expression was assessed by western blotting and ELISA. Cell proliferation and migration were assessed by a (3)H-thymidine incorporation assay and the modified Boyden chamber assay, respectively. RESULTS:IL33, ST2L and IL1RAcP were expressed by alpha-SMA-positive myofibroblasts in the fibrosis of chronic pancreatitis. In humanpancreatic myofibroblasts, IL33 was weakly immunoexpressed without any stimuli, and this was markedly enhanced by IL1beta, tumour necrosis factor alpha (TNFalpha) and lipopolysaccharide (LPS) via the mitogen-activated protein kinase (MAPK)-dependent AP-1 activation pathway. ST2L mRNA was weakly detected in unstimulated cells, and IL4 and interferon gamma (IFNgamma) strongly enhanced ST2L expression via STAT6 and STAT1 signalling, respectively. IL33 rapidly induced the phosphorylation of MAPKs and IkappaBalpha, and enhanced the expression of inflammatory mediators (IL6, IL8, IP-10, Gro-alpha, Gro-beta and MCP-1) in IL4- or IFNgamma-pretreated cells. IL33 stimulated the proliferation and migration of pancreatic myofibroblasts. CONCLUSIONS:IL33 and its receptor complex (ST2L and IL1RAcP) constitute a novel signalling system which may play an important role in the pathogenesis of chronic pancreatitis.
Authors: Laura Barreyro; Britta Will; Boris Bartholdy; Li Zhou; Tihomira I Todorova; Robert F Stanley; Susana Ben-Neriah; Cristina Montagna; Samir Parekh; Andrea Pellagatti; Jacqueline Boultwood; Elisabeth Paietta; Rhett P Ketterling; Larry Cripe; Hugo F Fernandez; Peter L Greenberg; Martin S Tallman; Christian Steidl; Constantine S Mitsiades; Amit Verma; Ulrich Steidl Journal: Blood Date: 2012-06-21 Impact factor: 22.113
Authors: Jon Sponheim; Jürgen Pollheimer; Trine Olsen; Johanna Balogh; Clara Hammarström; Tamara Loos; Monika Kasprzycka; Dag Reidar Sørensen; Hogne Røed Nilsen; Axel M Küchler; Morten H Vatn; Guttorm Haraldsen Journal: Am J Pathol Date: 2010-10-29 Impact factor: 4.307
Authors: Cecilia A Larocca; John W McEvoy; Carla L Ellis; Jacqueline Junkins-Hopkins; Todd Kolb; Alan N Baer; Brian T Garibaldi Journal: Clin Rheumatol Date: 2011-06-28 Impact factor: 2.980
Authors: Xin Long; Michelle Daya; Jianping Zhao; Nicholas Rafaels; Huifang Liang; Joseph Potee; Monica Campbell; Bixiang Zhang; Maria Ilma Araujo; Ricardo R Oliveira; Rasika A Mathias; Li Gao; Ingo Ruczinski; Steve N Georas; Donata Vercelli; Terri H Beaty; Kathleen C Barnes; Xiaoping Chen; Qian Chen Journal: J Allergy Clin Immunol Date: 2017-02-09 Impact factor: 10.793
Authors: Scott Napier Byrne; Clare Beaugie; Clare O'Sullivan; Sarah Leighton; Gary M Halliday Journal: Am J Pathol Date: 2011-05-13 Impact factor: 4.307
Authors: Rebecca L Maywald; Stephanie K Doerner; Luca Pastorelli; Carlo De Salvo; Susan M Benton; Emily P Dawson; Denise G Lanza; Nathan A Berger; Sanford D Markowitz; Heinz-Josef Lenz; Joseph H Nadeau; Theresa T Pizarro; Jason D Heaney Journal: Proc Natl Acad Sci U S A Date: 2015-04-27 Impact factor: 11.205